UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

SEC FILE NUMBER
 
000-54402
 
CUSIP NUMBER
 
090655408

(Check one):  [X] Form 10-K [   ] Form 20-F [   ] Form 11-K [   ] Form 10-Q [   ] Form 10-D [   ] Form N-CEN
        [   ] Form N-CSR

For Period Ended: December 31, 2019
[   ] Transition Report on Form 10-K
[   ] Transition Report on Form 20-F
[   ] Transition Report on Form 11-K
[   ] Transition Report on Form 10-Q
For the Transition Period Ended: __________________________

Read Instruction (on back) Before Preparing Form.  Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:______________________________________________________________


PART I - REGISTRANT INFORMATION

BIORESTORATIVE THERAPIES, INC.
Full Name of Registrant


Former Name if Applicable

40 Marcus Drive
Address of Principal Executive Office (Street and Number)

Melville, New York  11747
City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.  (Check box if appropriate)

[ X ]
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
[   ]
(b)
The subject annual report, semi-annual report, transition report on Form10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
[   ]
(c)
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 11-K, 20-F, 10-Q, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period.

As previously reported on the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 20, 2020, on such date, the Company filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Eastern District of New York (the “Bankruptcy Filing”).
During the period leading up to and since the Bankruptcy Filing, the Company has been principally engaged in addressing bankruptcy-related matters. The Company’s financial, accounting and administrative personnel and consultants have devoted substantially all of their time to the maintenance of the Company’s ongoing operations, including the development of the Company’s post-petition strategy and negotiations with regard to the potential sale of its assets.


As a result of the increased burdens placed upon the Company’s financial, accounting and administrative staff and consultants, as described above, and the lack of  Company financial resources to devote to the preparation and audit of its financial statements for the year ended December 31, 2019 and the preparation of its Annual Report on Form 10-K for such year (the “10-K”), the Company will not be able to timely file the 10-K.




PART IV - OTHER INFORMATION

(1)
Name and telephone number of person to contact in regard to this notification:
   
 
Mark Weinreb
(631)             760-8100
(Name)
(Area Code) (Telephone Number)
   
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed?  If answer is no, identify report(s).  [ X  ] Yes     [   ] No
   
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [  ] Yes   [   ] No    See below.
   
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Explanation of Anticipated Change

Reference is made to PART III – NARRATIVE.

BIORESTORATIVE THERAPIES, INC.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

 
 
       
Date:  March 31, 2020
By:
/s/ Mark Weinreb
 
    Mark Weinreb
 
    Chief Executive Officer
 
       


INSTRUCTION:  The form may be signed by an executive officer of the registrant or by any other duly authorized representative.  The name and title of the person signing the form shall be typed or printed beneath the signature.  If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

GENERAL INSTRUCTIONS
1.
This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under the Securities Exchange Act of 1934.
2.
One signed original and four conformed copies of this form and amendments thereto must be completed and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations under the Act. The information contained in or filed with the form will be made a matter of public record in the Commission files.
3.
A manually signed copy of the form and amendments thereto shall be filed with each national securities exchange on which any class of securities of the registrant is registered.
4.
Amendments to the notifications must also be filed on Form 12b-25 but need not restate information that has been correctly furnished. The form shall be clearly identified as an amended notification.
5.
Interactive data submissions. This form shall not be used by electronic filers with respect to the submission or posting of an Interactive Data File (§232.11 of this chapter). Electronic filers unable to submit or post an Interactive Data File within the time period prescribed should comply with either Rule 201 or 202 of Regulation S-T (§232.201 and §232.202 of this chapter).
BioRestorative Therapies (PK) (USOTC:BRTXQ)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more BioRestorative Therapies (PK) Charts.
BioRestorative Therapies (PK) (USOTC:BRTXQ)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more BioRestorative Therapies (PK) Charts.